Patients with early stage breast cancer who received breast-conserving surgery and were eligible for observation were more likely to undergo adjuvant radiotherapy in facilities performing APBI.
The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology have issued a joint consensus guideline update for the use of radiotherapy following mastectomy in patients with breast cancer.
Primary prophylaxis with G-CSF may modestly reduce neutropenia-related hospitalization in patients with breast cancer receiving docetaxel and cyclophosphamide or docetaxel, carboplatin, and trastuzumab.
Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
Bioimpedance spectroscopy (BIS) effectively assesses for subclinical breast cancer-related lymphedema in patients at risk, and accurately assess patients for response to treatment.
Inducing quiescent dormancy with conventional chemotherapy makes cancer cells more susceptible to immunotherapy, thereby minimizing potential for tumor recurrence.
Natural language processing (NLP) software correlated key characteristics expressed verbally in mammography reports with pathologic findings, providing an accurate indication for biopsy referral.
An experimental drug, AMPI-109, shows promise as an immunotherapy that sensitizes triple-negative breast cancer cells, enhancing the effectiveness of the drug.
African American survivors of breast cancer experience significant problem burden during the first 5 years after diagnosis and treatment.
A Systematic Review and Meta-analysis of Harmonic Technology Compared With Conventional Techniques in Mastectomy and Breast-conserving Surgery With Lymphadenectomy for Breast Cancer
[Breast Cancer: Targets and Therapy] This research compares Harmonic technology and conventional techniques for a range of clinical outcomes and complications in both mastectomy and BCS patients, including axillary lymph node dissection.
Greater negative beliefs regarding the challenges of their aromatase inhibitor treatment more likely to lead to nonadherence.
Skilled radiologists see abnormalities immediately, and researchers want to learn how they do it.
A novel sentinel lymph node (SLN) radiotracer, 99mTC-rituximab, demonstrated nearly 100% detection/success rate in SLN and metastasis in breast cancer.
The 70-gene signature test, in combination with standard clinical-pathologic criteria, may help clinicians decide whether patients with early stage breast cancer who are at high clinical risk require adjuvant chemotherapy.
Adolescent girls from BRCA1/2 mutation-positive and breast cancer families have high self-esteem but greater breast-cancer specific-distress.
Postmastectomy pain syndrome (PMPS) is a debilitating late effect of surgery and radiation therapy for breast cancer.
Negative patient expectations are associated with an increased risk of adverse events in patients with breast cancer undergoing endocrine therapy.
Estrogen receptor (ER)-positive breast cancers are often not a single tumor but a composite of related tumors, referred to as sub-clones.
Routine testing for hormone receptors in tissue obtained in a first needle biopsy for ductal carcinoma in situ (DCIS).
Change in tumor size at week 8 may predict overall survival during first-line therapy in patients with metastatic breast cancer.
Participation in exercise may reduce mortality compared with nonparticipation in patients with breast cancer.
Losing weight through diet or diet and exercise improves risk for cancer in overweight or obese postmenopausal women. Although exercise alone can help maintain weight loss, it is not as effective as diet and exercise.
Consensus guideline states that a 2 mm margin is enough to guard against recurrences while reducing need for additional operations for women with DCIS who undergo breast-conserving surgery.
ESR1 mutations are more frequent in patients with estrogen receptor (ER)-positive metastatic breast cancer that are treated with aromatase inhibitors, according to recent study data.
Study data indicate that women who ate a Western diet also had 46 percent higher risk of breast cancer.
Measures of severe skeletal muscle loss, or sarcopenia, are associated with toxicity outcomes and survival in patients with metastatic breast cancer receiving first-line taxane-based chemotherapy.
Survival among women age 40 years and younger with breast cancer appears to vary according to breast cancer subtype, with age particularly prognostic for women with luminal type breast cancers.
Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of Trastuzumab
Therapies targeting ErbB2 (HER2), such as trastuzumab (Herceptin), are often associated with cardiovascular side effects. ErbB2 was recently found to also be expressed by vascular endothelial cells, and is an example of how tissue growth and blood vessel patterning are integrated at the molecular level.
Cognitive decline associated with adjuvant chemotherapy was more likely to occur in older patients, particularly those whose treatment included docetaxel.
Acupressure reduced persistent fatigue in women who had been treated for breast cancer, improving both sleep and quality of life.
MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.
Patients with kataegis, a recently discovered phenomenon in which multiple mutations cluster in a few hotspots in a genome, have less invasive tumors and better prognoses.
Preliminary results of a prospective, phase II trial show that once-daily accelerated partial breast irradiation (APBI) effectively prevented recurrence of cancer in the treated breast at a median 34 months after treatment.
A Systematic Review and Meta-analysis of the Risk of Diarrhea Associated With Vandetanib Treatment in Carcinoma Patients
[OncoTargets and Therapy] This research examines overall risks of all-grade and high-grade diarrhea during vandetanib treatment, to gain a better understanding of its prediction and management.
Risk factors for chronic pain after breast cancer surgery include axillary lymph node dissection, younger age, and radiation therapy. Only axillary lymph node dissection is a high-yield target for a modifiable risk factor to prevent the persistent pain after breast cancer surgery.
A Mediterranean-style diet can help protect against diabetes, cardiovascular disease, and breast cancer,research indicates.
The definition of dense breasts can range from 6.3 to 84.5 percent of patients, depending on radiologist.
A new technique combines imaging and mathematics to identify aggressive forms of ductal carcinoma in situ (DCIS), or stage 0 breast cancer, from nonaggressive varieties.
A first-line triplet chemoimmunotherapy regimen comprised of paclitaxel, capecitabine, and bevacizumab followed by capecitabine and bevacizumab alone as maintenance therapy is highly active with a manageable safety profile in patients with triple-negative breast cancer.
Supine Position Better Informs Surgeons About Tumor Size and Location Before Lumpectomy for Breast Cancer
Considerable deformity of the breast and tumor position occur when placing patients in the prone (face down) position to obtain pre-operative MRI of the breast, compared with placing patients in the supine (face up) position.
Moderate physical activity can ease the stress that impairs memory among breast cancer survivors, research indicates.
The protein CBX8 uses a previously unknown mechanism to promote the origin of breast tumors, or tumorigenesis, in the most lethal forms of breast cancer, according to new research.
Memory problems in breast cancer survivors appear associated with the high stress load these patients experience rather than their treatment, and moderate-to-vigorous physical activity may help subjective memory in these patients.
Bacteria differ between healthy breasts and those with cancer, and beneficial bacteria may actually be protecting women against cancer; a finding that may lead to using probiotics to prevent breast cancer.
A single dose and a beam of light can kill up to 95% of cancer cells in 2 hours, according to preclinical research on a novel approach to tumor resection. Photodynamic cancer therapy may be a treatment option for people whose tumors are inoperable or hard-to-reach.
Relaxing acupressure resulted in significant improvement in persistent fatigue, sleep quality, and quality of life among survivors of breast cancer, a recent study has shown.
The Patient-Owned Survivorship Transition Care for Activated, Empowered survivors (POSTCARE) intervention resulted in clinically meaningful improvements in 3 domains of quality of life (QoL) among survivors of breast cancers.
A group of researchers sought to examine the physical functioning of patients with breast cancer, in various age brackets, who were enrolled in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) phase III trial.
New screening device provides images with 6 times better contrast of breast tumors and approximately half the radiation dose of standard mammography.
Many Older Women With Early Stage Breast Cancer Are Susceptible to Functional Decline After Starting Treatment
Approximately 20% of older women with stage I-III breast cancer lost the ability to complete some basic tasks of independent living within 1 year of starting treatment. However, an assessment tool can identify those women at greatest risk of posttreatment functional decline.
Preoperative smoking is associated with increased risk for breast cancer events and distant metastasis in women treated with aromatase inhibitors (AIs). Hampering the utility of AIs, a common treatment for breast cancer, is yet another health risk associated with smoking.
Nonadherence to Noncancer Medication Schedules Predicts Adherence to Adjuvant Hormone Therapy for Breast Cancer
Patients who do not adhere to their medication schedules for chronic conditions prior to a breast cancer diagnosis were twice as likely to skip oral adjuvant hormonal therapy.
Employing a prone position during preoperative breast magnetic resonance imaging might introduce error.
Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.
The addition of a patient navigation component to a population-based IT system boosted screening rates for breast cancer, cervical cancer, and colorectal cancer in patients at high risk for nonadherence.
Trastuzumab-related cardiotoxicity was far lower in Taiwanese women with breast cancer compared with previously published results, according to recent study data.
New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
Researchers demonstrate how breast cancer cells invade bone marrow, where they escape chemotherapy and hormonal therapies that would otherwise eliminate the cancer cells.
A gene expression pattern in the noncancerous tissues surrounding estrogen receptor-positive breast cancer is associated with lower 10-year survival rates.
Patient Stress Level Influences Best Type of Couples' Therapy for Patients With Breast Cancer and Their Partners
Distressed patients with breast cancer benefit most from a couple-focused supportive group therapy, while less distressed patients benefit more from a structured, skills-based, couples-focused group therapy.
Following a healthy lifestyle could reduce the risk of developing breast cancer for women already at high risk for the disease due to genetic risk and family history.
The drug denosumab, which blocks a bone gene, may also prevent breast cancer caused by a BRCA1 mutation. This already approved drug could be available quickly, and would be the first drug for breast cancer prevention.
The incidence of cardiovascular events was down for patients with non-metastatic breast cancer that exercise.
Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors underscores that "the benefit from genetic testing comes from acting on the test results," not just the testing itself, a study presented at the ASCO 2016 Annual Meeting concluded.
A substantial and independent association between individual provider, the treatment center, and type of breast surgery among elderly women with breast cancer suggests the presence of physician and institutional biases. That is the conclusion of a Medicare claims database review presented at the 2016 ASCO Annual Meeting.
"Routine use of ALND should be abandoned." That's the conclusion based on 10-year survival data from the ACOSOG Z0011 randomized study comparing sentinel lymph node dissection alone to ALND in women with clinical T1-2 N0 M0 breast cancer and a positive sentinel node presented at the 2016 ASCO Annual Meeting.
The genetically engineered epothilone analog, utidelone, in combination with capecitabine significantly improved progression-free survival and objective response rates in patients with metastatic breast cancer who were heavily pretreated, compared with capecitabine alone, results of a phase 3 trial presented at the 2016 ASCO Annual Meeting have shown.
Tailored dose-dense chemotherapy significantly improved event-free survival and also showed efficacy in relapse-free and overall survival compared with standard adjuvant chemotherapy in patients with high-risk breast cancer, according to results of the phase 3 PANTHER study reported at the 2016 ASCO Annual Meeting.
Interim joint analysis of the ABC Trials showed invasive disease-free survival was significant for superiority of anthracycline/taxane-based chemotherapy regimens (TaxAC) relative to docetaxel plus cyclophosphamide, according to study results presented at the 2016 ASCO Annual Meeting.
Palbociclib Plus Fulvestrant Provides Significant Benefit in Hormone Receptor-Positive Metastatic Breast Cancer
ESR1 mutations detected in plasma circulating tumor DNA were identified in a high percentage of patients with hormone receptor-positive metastatic breast cancer, confirming an important role in endocrine resistance, according to an analysis of data from the phase 3 PALOMA-3 reported at the 2016 ASCO Annual Meeting.
ESR1 Mutations Predict Worse Outcome in HR-positive Metastatic Breast Cancer Treated with Aromatase Inhibitors
The presence of circulating ESR1 somatic mutations at disease progression in patients with HR-positive metastatic breast cancer treated with first-line AIs represent a strong and independent poor prognostic value for overall survival but no predictive value, a study presented at the 2016 ASCO Annual Meeting has found.
A cocktail of 3 drugs shrank triple-negative breast cancer (TNBC) by killing off cancer cells and halting new tumor growth, a new study conducted in mice and lab-grown human cells has shown.
Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.
Scientists discovered the compound eCF506. This compound was more effective than existing medicines at targeting breast cancer cells because it more selectively inhibited SRC tyrosine kinase.
A potential cancer therapy with a unique strategy to block the mTOR molecule has been designed. This new mTOR-inhibiting compound reduced the size of tumors resistant to earlier-generation mTOR inhibitors.
Vitamin D and androgen receptor-targeted therapy successfully reduced growth and induced death of cancerous cells in a cell culture model of triple-negative breast cancer.
Training Patients With Breast Cancer to Achieve Prolonged Breath Holds Could Improve Targeted Radiotherapy
Patients with breast cancer can be trained to achieve a breath hold lasting more than 5 minutes, allowing for targeted administration of radiotherapy with a single dose per daily session that can minimize damage to surrounding tissues.
A new drug candidate reduced the growth of tumors in a mouse model of triple negative breast cancer (TNBC) by targeting the RNA, or expression, of a gene only expressed in the diseased cells.
Both automated and clinical assessments of breast density are associated with breast cancer risk.
No Clinical Benefit to Expanding Gene Panel Beyond Ovarian and Breast Cancer Genes in High-risk Women
Expanding a panel of tested genes beyond the known breast and ovarian cancer-specific genes in patients with breast and ovarian cancer did not confer any clinical benefit.
Combining 2 existing chemotherapy drugs, a DNMT1 inhibitor and a histone deacetylase inhibitor, reduced the numbers of cancer stem cells and improved survival in a mouse model.
Researchers examined possible correlations between complementary and alternative medicine and delayed initiation of clinically indicated chemotherapy among patients with early-stage breast cancer.
Disparities in BRCA1/2 testing in black and white women is attributable to differences in physician recommendations, according to a recent study.
Patients undergoing treatment for breast cancer with trastuzumab-containing regimens need to be monitored for heart damage regardless of age.
For women younger than 45 years with early stage breast cancer that has not spread to the lymph nodes, opting for breast-conserving therapy with RT was associated with higher risk of local recurrence over 20 years compared with mastectomy and no RT.
Amplification of the JAK2 gene frequently occurs in triple-negative breast cancer (TNBC), suggesting that specific inhibitors of JAK2 should be investigated in TNBC.
Delayed radiation therapy (RT) after surgery significantly increased the risk of recurrent disease in women treated for very early breast cancer.
Risk for Fatal Cardiovascular Events Not Increased in Patients With Breast Cancer Taking Aromatase Inhibitors
Risk of the most serious cardiovascular events, cardiac ischemia and stroke, were not increased in breast cancer patients taking aromatase inhibitors compared with tamoxifen users.
Disparities in the gut microbiome between healthy people and women with estrogen-driven breast cancer may indicate possible biomarkers based on the microbiome that could help to mitigate the risk of certain cancers.
Combining trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab for patients with HER2-positive invasive breast cancer.
[Breast Cancer: Basic and Clinical Research] The review examines the standard systemic and future treatment options in metastatic triple-negative breast cancer.
Comprehensive patient education that includes information on breast reconstruction, with photos, can help women with breast cancer make more informed decisions about their treatment options.
Postmenopausal women who stayed on a low fat diet for an extended time had a reduced risk of death from invasive breast cancers, according to clinical trial data.
Prophylactic nipple-sparing mastectomy is as effective at preventing breast cancer as more invasive surgeries, according to a multi-institution study.
The BRCA1 mutation may speed the aging of a woman's ovaries,according to a recent report.
Longer survival was achieved with stereotactic radiosurgery (SRS) alone than with whole-brain radiation therapy (WBRT) in patients with fewer than 4 brain metastases from NSCLC or breast cancer.
Anthracycline chemotherapy, such as doxorubicin and daunorubicin, is not associated with lasting cognitive decline among breast cancer survivors.
The risk of the most serious cardiovascular events, including cardiac ischemia and stroke, was not higher for breast cancer survivors who received an aromatase inhibitor (AI) compared with tamoxifen users.
Significant weight loss through calorie restriction, but not moderate weight loss through a low-fat diet, was linked to reduced breast cancer growth in a preclinical study.
A study examined the relation between various forms of breast cancer therapies and risk of congestive heart failure.
A biosimilar agent to pegfilgrastim was therapeutically equivalent and comparable to the reference agent in terms of efficacy and safety in the prevention of chemotherapy-induced neutropenia in patients with early stage breast cancer receiving chemotherapy.
Latina women in the United States nearly doubled their rate of screening for breast cancer after visits from a health-promoting promotora.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|